IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest digital blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data. Our proprietary technology can detect novel signature sequences, biomarkers, and polygenic risk scores by integrating “multi-omics” data, electronic healthcare record (EHR) data, and textual information such as scientific manuscripts.
There is an historic lack of diversity in biomedical research, including leading-edge genetic investigations like genome-wide association studies (GWAS).
Only 3% of genetic data collected worldwide is from people of African ancestry. However, almost 20% of the world's population is of African descent.
Precision medicine is leveraging the genome to identify the underlying causes of human disease. Because African populations are the most genetically diverse in the world, the power of precision medicine is limited when they are not present in research and clinical trials.
Underrepresentation in research also impacts how the results of precision medicine clinical studies can be applied. These populations will essentially be excluded from the benefits of the advances these studies yield.
We are utilizing state-of-the-art next-generation sequencing (NGS) technology to generate a whole-genome sequence (WGS) database of 1 million people from indigenous populations across the African diaspora. Increased diversity of genetic data will facilitate more robust research and accelerate scientific discovery.
Increased diversity of genomic data will support discovery of novel biomarkers and potential drug targets as well as facilitate broader efficacy and safety in drug research and development by increasing participation of underrepresented populations in clinical trials.
Improved representation of underserved populations in biomedical research provides greater diversity in data resources to understand the molecular pathology of human disease, reduce and eliminate health disparities, and move towards health equity.
The global COVID-19 pandemic highlights the importance of diversity in infectious disease, therapeutics, and prophylactic vaccine research. International public health initiatives have recently been initiated to facilitate the use of NGS technology in the identification and management of pathogenic outbreaks.
The Africa Centers for Disease prevention and Control (Africa CDC) in partnership with the African Union Commission (AUC) launched the Pathogen Genomics Initiative (PGI). This $100M project will fully integrate NGS technology into Africa CDC's Institute for Pathogen Genomics' (IPG) plan "...to integrate pathogen genomics and bioinformatics into public health surveillance, outbreak investigation, and improved disease control and prevention."